EU Approves Enhertu Plus Pertuzumab as First New First-Line Regimen in Over a Decade for HER2-Positive Metastatic Breast Cancer

First New First-Line Regimen Approved in Over a Decade

The European Commission has recently approved Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer. This marks the first new first-line regimen approved in this field in more than a decade, representing a significant shift in the treatment landscape for HER2-positive breast cancer.

Advantages of the Enhertu Combination

Enhertu is an antibody-drug conjugate (ADC) that delivers potent chemotherapy directly to cancer cells by targeting the HER2 receptor. When combined with pertuzumab, it provides dual blockade of the HER2 signaling pathway, enhancing anti-tumor activity. Clinical studies have shown that this combination significantly extends progression-free survival (PFS) compared to traditional first-line therapies, with a manageable safety profile.

Implications for Patients

• Provides a new standard first-line treatment option for patients with HER2-positive metastatic breast cancer
• May offer better efficacy and survival benefits compared to traditional chemotherapy plus targeted therapy
• Fills the gap left by the lack of new regimens in this field for over a decade

Expert Perspectives

The oncology community has welcomed this approval with high recognition. Experts point out that the approval of Enhertu plus pertuzumab not only enriches clinical treatment options but also lays the foundation for future exploration of ADC drugs in breast cancer. As more clinical data accumulate, this regimen is expected to further optimize treatment strategies.

Health Management Recommendations

For breast cancer patients and high-risk populations, regular screening and early detection remain crucial. During treatment, patients should closely monitor their health status and work with their physicians on individualized treatment plans. Additionally, daily health management is equally important — Xiaoshu Health App can sync with Apple Health to track relevant metrics, helping patients record weight, heart rate, activity levels, and other data to support recovery management during treatment.